Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

170.16USD
15 Oct 2019
Change (% chg)

$1.22 (+0.72%)
Prev Close
$168.94
Open
$168.95
Day's High
$170.63
Day's Low
$168.91
Volume
381,704
Avg. Vol
869,505
52-wk High
$192.67
52-wk Low
$114.27

Latest Key Developments (Source: Significant Developments)

Abbvie And Allergan Receive Second Request From FTC On Pending Transaction
Saturday, 28 Sep 2019 

Sept 27 (Reuters) - Abbvie Inc ::ABBVIE AND ALLERGAN RECEIVE SECOND REQUEST FROM FEDERAL TRADE COMMISSION ON PENDING TRANSACTION.ABBVIE INC - CO AND ALLERGAN ARE COOPERATING FULLY WITH FTC AND CONTINUE TO EXPECT TO CLOSE TRANSACTION IN EARLY 2020.  Full Article

Evolus Expects 2019 Revenue To Be Back-loaded Towards Q4: Conf. Call
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Evolus Inc ::SAYS OF CONSUMER SWITCH FROM OTHER TOXINS TO JEUVEAU, APPROXIMATELY 70% CAME FROM BOTOX COSMETICS: CONF. CALL.SAYS EXPECTS 2019 REVENUE TO BE BACKLOADED TOWARDS THE FOURTH QUARTER.  Full Article

Allergan Voluntarily Recalls Biocell® Textured Breast Implants And Tissue Expanders
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Allergan plc ::ALLERGAN VOLUNTARILY RECALLS BIOCELL® TEXTURED BREAST IMPLANTS AND TISSUE EXPANDERS.ALLERGAN PLC - GLOBAL ACTION FOLLOWS NOTIFICATION OF UPDATED SAFETY INFORMATION FROM U.S. FOOD AND DRUG ADMINISTRATION (FDA) --.ALLERGAN PLC - FDA DOES NOT RECOMMEND REMOVAL OR REPLACEMENT OF TEXTURED BREAST IMPLANTS IN ASYMPTOMATIC PATIENTS.ALLERGAN PLC - SMOOTH AND MICROCELL® BREAST IMPLANTS AND TISSUE EXPANDERS NOT IMPACTED.ALLERGAN PLC - SMOOTH AND MICROCELL BREAST IMPLANTS AND TISSUE EXPANDERS NOT IMPACTED.ALLERGAN PLC - GLOBAL RECALL DOES NOT AFFECT ALLERGAN'S NATRELLE SMOOTH OR MICROCELL BREAST IMPLANTS AND TISSUE EXPANDERS.  Full Article

Ironwood Pharmaceuticals Inc - On July 22 Parties To ANDA Lawsuit Filed A Proposed Stipulation
Tuesday, 23 Jul 2019 

July 22 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - ON JULY 22 PARTIES TO ANDA LAWSUIT FILED A PROPOSED STIPULATION.IRONWOOD PHARMACEUTICALS INC - STIPULATION PROVIDES FOR ANDA LAWSUIT TRIAL TO BE RESCHEDULED TO BEGIN ON JAN 7, 2020.  Full Article

AIG Names Karen Ling Executive Vice President, Chief Human Resources Officer
Monday, 22 Jul 2019 

July 22 (Reuters) - American International Group Inc ::AIG NAMES KAREN LING EXECUTIVE VICE PRESIDENT, CHIEF HUMAN RESOURCES OFFICER.AIG - LING JOINS AIG FROM ALLERGAN PLC.  Full Article

Allergan Declares Q3 Cash Dividend Of $0.74 Per Ordinary Share
Friday, 19 Jul 2019 

July 19 (Reuters) - Allergan plc ::ALLERGAN DECLARES THIRD QUARTER 2019 CASH DIVIDEND OF $0.74 PER ORDINARY SHARE.  Full Article

Allergan Says FDA Accepted Co's New Drug Application
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Allergan plc ::U.S. FDA ACCEPTS ALLERGAN'S NEW DRUG APPLICATION FOR BIMATOPROST SUSTAINED-RELEASE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.ALLERGAN PLC - FDA IS EXPECTED TO TAKE ACTION ON NDA BY END OF FIRST HALF OF 2020..  Full Article

FDA Approves Botox For Pediatric Patients With Upper Limb Spasticity
Friday, 21 Jun 2019 

June 21 (Reuters) - Allergan plc ::FDA APPROVES BOTOX® (ONABOTULINUMTOXINA) FOR PEDIATRIC PATIENTS WITH UPPER LIMB SPASTICITY.ALLERGAN PLC - FDA IS ALSO REVIEWING AN ADDITIONAL SBLA FOR USE OF BOTOX TO TREAT PEDIATRIC PATIENTS WITH LOWER LIMB SPASTICITY.ALLERGAN PLC - FDA APPROVES BOTOX® (ONABOTULINUMTOXINA) FOR PEDIATRIC PATIENTS WITH UPPER LIMB SPASTICITY.ALLERGAN PLC - DECISION ON ADDITIONAL SBLA EXPECTED IN Q4 OF THIS YEAR..ALLERGAN - APPROVAL BASED ON DATA FROM TWO PHASE 3 STUDIES EVALUATING SAFETY & EFFICACY OF BOTOX.ALLERGAN - APPROVED RECOMMENDED DOSE PER TREATMENT SESSION IS 3 UNITS PER KILOGRAM TO 6 UNITS PER KILOGRAM DIVIDED AMONG AFFECTED MUSCLES OF UPPER LIMB.ALLERGAN PLC - TREATMENT WITH BOTOX IS NOT MEANT TO REPLACE EXISTING PHYSICAL THERAPY OR OTHER REHABILITATION THAT MAY HAVE BEEN PRESCRIBED.  Full Article

Richter, Allergan extend Cariprazine agreement to Latin America
Friday, 21 Jun 2019 

June 21 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU::.  Full Article

Rising Pharmaceuticals Announces The Launch Of Mesalamine Suppository
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Rising Pharmaceuticals::RISING PHARMACEUTICALS - ANNOUNCED U.S. LAUNCH & COMMERCIAL SHIPMENT OF A GENERIC VERSION OF CANASA, (MESALAMINE) SUPPOSITORY, IN 1,000 MG STRENGTH.  Full Article

Photo

FTC requests AbbVie, Allergan for more information on $63 billion deal

The U.S. Federal Trade Commission (FTC) has requested for more information from AbbVie Inc and botox maker Allergan Plc on their $63 billion deal, the companies said on Friday.